DexCom Stock Price and Value Analysis

Should you buy DexCom stock? (NasdaqGS:DXCM). Let's see how it does in our automated value investing analysis system.

  • This company is solid.
  • This company has stable growth.
  • This company is not making money.
  • This stock looks overpriced.
  • This company pays no dividend.

Inside the DXCM Numbers

DXCM Price
(DexCom stock price per share)
[?] PE Ratio versus Sector 10% higher than other Healthcare stocks
[?] PE Ratio versus Industry 100% lower than other Diagnostics & Research stocks
[?] Cash Yield 0.24%
[?] Free Cash Flow Jitter 23%

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 13,688,666 shares shorted. With 390,689,532 shares available for purchase and an average trading volume over the past 10 trading days of 2,866,180, it would take at least 4.776 days for all of the short holders to cover their shorts.

Is DexCom Stock on Sale?

Based on our analysis, we believe that you should not buy DexCom right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy DXCM Stock?

Does DexCom have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.